The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Innovative induction regimens, either with new combinations of well-established drugs or recently approved agents, or novel treatment schedules, are currently under investigation to improve outcomes for the treatment of de novo acute myeloid leukemia (AML). Gemtuzumab ozogamicin (GO), when added to intensive chemotherapy, has been associated with improved outcomes in this patient population; however, the best use of GO in induction therapy remains unclear.1
During the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, investigators presented findings from two studies investigating whether GO would improve event-free survival (EFS) when used in combination with cladribine, high-dose cytarabine, granulocyte colony-stimulating factor (G-CSF) and mitoxantrone (CLAG-M)1 or added to cytarabine instead of idarubicin2 here, we summarize key results.
Figure 1. Study design*
G-CSF, granulocyte colony-stimulating factor; GO, gemtuzumab ozogamycin; IV, intravenous; SC, subcutaneous.
*Adapted from Godwin et al.1
Total number of patients was 66 with a median age of 65 years (range, 19–80). The majority of patients had AML (80%) and 42% of patients had a secondary disease. Eighteen patients were treated in phase I cohort and 60 patients were included in the RP2D cohort (Table 1).
Table 1. Patient characteristics*
AML, acute myeloid leukemia; MDS-EB2, myelodysplastic syndromes with excess blasts 2; RP2D, recommended phase 2 dose; TRM, treatment-related mortality. |
||
Characteristic, % |
Phase I cohort |
RP2D cohort |
---|---|---|
Median age, years (range) |
66 (29–78) |
65 (19–80) |
Diagnosis |
||
AML |
78 |
80 |
MDS-EB2 |
22 |
12 |
Other |
0 |
8 |
Secondary disease |
44 |
42 |
Risk category |
||
Favorable |
39 |
35 |
Intermediate |
28 |
20 |
Adverse |
33 |
45 |
TRM score, median (range) |
3.9 (0.14–10.4) |
3.5 (0.02–11.8) |
Phase I results yielded a RP2D of 3 mg/m2 GO given on Days 1, 4, and 7; AEs recorded in this cohort appeared to be similar to those seen with CLAG-M alone. Dose-limiting toxicities included Grade 3 left ventricular dysfunction, posterior reversible encephalopathy syndrome, intracranial hemorrhage, and Grade 4 aminotransferase level increase.
Outcomes from phase II cohort are summarized below:
A validation cohort of 174 patients who were treated with CLAG-M was used to compare results with CLAG-M plus GO.
This study suggested that adding fractionated doses of GO to CLAG-M chemotherapy may be a safe option with promising anti-leukemic activity for adult patients with newly diagnosed AML or other high-grade myeloid neoplasm. The benefit appeared to be greater in patients with favorable-risk disease when compared to CLAG alone. Time to platelet and neutrophil recovery was delayed when GO was added.
Figure 2. Study design*
AraC, cytosine arabinoside; CR, complete remission; GO, gemtuzumab ozogamicin; h, hours.
*Adapted from Lambert et al.2
†Patients over 70 years of age, AraC dose was 1 g/m2/12h
The total number of patients included in the analysis was 214 (Table 2).
Table 2. Patient characteristics*
GO, gemtuzumab ozogamicin; IQR, interquartile range; WBC, white blood cell. |
||
Characteristic, % |
Standard arm |
GO arm |
---|---|---|
Male sex |
48 |
62 |
Median age, years (IQR) |
69 (62–79) |
70.5 (61–80) |
Median WBC, × 109/L (IQR) |
5.8 (0.4–275.4) |
3.8 (0.5–241.5) |
Intermediate-risk cytogenetics |
94 |
93 |
NPM1 mutation |
35 |
26 |
FLT3-ITD mutation |
17 |
15 |
In conclusion, this study failed to demonstrate an additional benefit of GO over idarubicin as a frontline therapy for older patients with de novo AML. In terms of safety, GO was associated with more SAEs compared with standard therapy which may limit the transplant indication in patients.
Watch this video with Amir Fathi where he talks about the potential impact of new immunotherapy modalities in AML, here.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content